TD Cowen Lowers PT on MetLife (MET), Keeps a Buy

Core Viewpoint - MetLife, Inc. is considered one of the most undervalued long-term stocks to buy according to analysts, despite a recent price target reduction from $91 to $88 by TD Cowen while maintaining a Buy rating [1] Financial Performance - In Q4 2025, MetLife reported a revenue growth of 22.56% year-over-year, reaching $24.19 billion, although it missed estimates by $7.44 billion [2] - The earnings per share (EPS) for the quarter was $2.49, exceeding consensus estimates by $0.15 [2] Segment Performance - The Group Benefits segment saw a 12% year-over-year increase in adjusted earnings, totaling $465 million in Q4 [4] - Retirement and Income Solutions earnings improved by 18% year-over-year, reaching $454 million [4] - MetLife Investment Management, a newly formed business segment, generated $60 million in adjusted earnings for 2025, with assets under management increasing to $742 billion from approximately $600 billion a year earlier due to the PineBridge acquisition [5] Future Outlook - The company anticipates double-digit adjusted EPS growth for fiscal 2026, along with an adjusted return on equity (ROE) of 15% to 17% [5] Company Overview - MetLife, Inc. provides a range of services including insurance, annuities, employee benefits, and asset management across the United States and international markets, covering life, dental, disability, property, and casualty insurance, as well as retirement and savings products for individuals and institutions [6]